– New roles for Andreas Boos, Chris Bernard and Dr. Achim Plum
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced several changes in its Management Board, effective as of today.
Andreas Boos, CTO and co-founder of Curetis, is stepping down from the Management Board of Curetis N.V. to focus on his role as the group´s CTO and program director for the Gyronimo platform development. Andreas will continue to serve as one of the managing directors of Curetis GmbH. This move is part of the continuing evolution of Curetis´ organization towards a more commercially driven enterprise.
Chris Bernard, President and CEO of Curetis USA Inc, has been appointed as Executive VP of Global Sales, assuming direct management responsibility for the EMEA sales organization. He will report directly to Curetis N.V. CEO Oliver Schacht and will inform the Supervisory Board on all sales-related matters.
Dr. Achim Plum, COO of Curetis, will assume the role of Chief Business Officer (CBO) for Curetis N.V. He will continue to lead EMEA marketing, customer service & support, scientific affairs, and global business development. In addition, he is serving as one of the managing directors of Ares Genetics GmbH in Vienna to accelerate and drive the partnering and development of GEAR related programs forward.
“The changes in our Management Board reflect the increasing commercial focus of the company,” said Dr. Oliver Schacht, CEO of Curetis. “The new roles and responsibilities of Andreas, Chris and Achim will enable us to maximize the value of our recent product and technology additions.”